IDPH--Positive preliminary results for pivotal trial of ID

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
IDPH--Positive preliminary results for pivotal trial of ID

An SI Board Since June 1996

Posts	SubjectMarks	Bans	Symbol
1762	27	0	IDPH

Emcee: Roudy	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1412	Sources at a large HMO in my area say Rituxan will probably be approved for cov	Bob L	-	1/6/1998
1411	Contrarian, as long as one sticks to the labeling, I'd say the chances are	Pseudo Biologist	-	1/6/1998
1410	PB, Thanks for the inputs. What are the chances of getting HMOs, etc. to reim	contrarian	-	1/6/1998
1409	Contrarian, not sure if this new but I've heard from a couple of sources th	Pseudo Biologist	-	1/6/1998
1408	Howard, Hope you had a good holiday. Looks like the thread has died. It appea	contrarian	-	1/6/1998
1407	*OFF TOPIC* Howard, I mentioned this AXO before. If you still have an inte	Dettmer	-	12/26/1997
1406	News:http://biz.yahoo.com/bw/971216/genentech_idec_1.html	DZOO	-	12/18/1997
1405	Everything I know about the subject has been learned as an IDEC investor. I re	Howard Hoffman	-	12/16/1997
1404	Well you seem to be very up to speed on immunotherapy and monoclonal antibobies	Juergen	-	12/15/1997
1403	No, I have not. Why do you ask?	Howard Hoffman	-	12/15/1997
1402	Howard, have you heard of Altarex Corp, listed in Canada symbol AXO?	Juergen	-	12/14/1997
1401	More good news IDEC Pharmaceuticals Reports Interim Results of Phase I/II Tria	Howard Hoffman	-	12/10/1997
1400	The potential market is quite large. At least one billion... in the industry p	I. Luttichuys	-	12/10/1997
1399	<<I should add, Howard, that the cautious line would be to view SK's	Howard Hoffman	-	12/10/1997
1398	Bennett, off the subject but it would be a shame to visit Anchorage without goi	James Perry	-	12/9/1997
1397	Hello PB, This is something I just don't have any time to find out. I'	I. Luttichuys	-	12/6/1997
1396	Bennett, I've heard the current hypothesis is the CD4 issue with CE9.1 was	Peter Singleton	-	12/6/1997
1395	Bennett, what is known about the differences between these two MAbs? Are there	Pseudo Biologist	-	12/6/1997
1394	I should add, Howard, that the cautious line would be to view SK's backing	I. Luttichuys	-	12/6/1997
1393	Howard... the thing to watch are the CD4 cells... This has been a traditional p	I. Luttichuys	-	12/5/1997
1392	Matt-What are we doing giving work like that to ex-premiers, when we have ex-NB	Roger Cranwill	-	12/5/1997
1391	Roger Done Said: >of the curve in a market that will be unbelievably >pro	Matthew Wecksell	-	12/4/1997
1390	My concern about dropping CE9.1 is losing time-IDEC was on-track for marketing	Roger Cranwill	-	12/4/1997
1389	Any of our more medically-knowledgable posters wish to comment? To this layman	Howard Hoffman	-	12/4/1997
1388	It appears to me the announcement of the new arthritis drug being compared to C	Roger Cranwill	-	12/3/1997

Go to reply# or date (mm/dd/yy):